You are here: Industry Insights > patient

News List

Half of all kidney cancer patients initially misdiagnosed pharmatimes
November 01, 2018
Half of all patients with kidney cancer are initially misdiagnosed, data from Kidney Cancer UK’s patient survey has revealed.
Janssen unveils long-term data for HIV drug Symtuza pharmatimes
November 01, 2018
Janssen has unveiled new late-stage data on Symtuza showing positive long-term efficacy and safety in antiretroviral treatment-naïve adults with HIV...
REVOLUTION Medicines Announces First Patient Dosed with RMC-4630 americanpharmaceuticalreview
October 12, 2018
REVOLUTION Medicines announced dosing of the first patient in a Phase 1, open-label, monotherapy dose-escalation and expansion study of RMC-4630, the company’s lead investigational drug candidate targeting the enzyme SHP2.
First Patient Dosed in DSP-0509 Trial americanpharmaceuticalreview
September 14, 2018
Boston Biomedical has initiated clinical trial activities for DSP-0509, an investigational Toll-like receptor (TLR) 7 agonist. DSP-0509 is hypothesized to induce cytokine production, activate cytotoxic T lymphocytes, and sustain the immune-mediated antitu
Compugen Announces First Patient Dosed with COM701 americanpharmaceuticalreview
September 10, 2018
Compugen announced the first patient has been dosed in its Phase 1 clinical trial of COM701, a first-in-class cancer immunotherapy antibody targeting PVRIG.
To treat pain, you need to treat the patient worldpharmanews
May 08, 2018
People in chronic pain are some of the most difficult patients to treat. They have complex circumstances that medicine can't always remedy.
Bonesupport enrols first patient in injectable bone graft substitute trial europeanpharmaceuticalreview
May 26, 2017
Bonesupport, the Scandinavian medical technology company, has enrolled their first patient at the University of Texas Health Science Center at San Antonio into the company’s pivotal Investigational Device Exemption (IDE) trial.
RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA® Phase II Study for IBS-D b3cnewswire
April 26, 2017
RedHill Biopharma Ltd. announced enrollment of the last patient in the Phase II study with BEKINDA® (RHB-102)(1) 12 mg for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).
Polyganics Announces Enrollment of the First Patient in its PROTECT NEURO Study b3cnewswire
April 21, 2017
Polyganics announced today that it has enrolled the first patient in its international PROTECT NEURO study to treat and prevent symptomatic neuroma.
Verona Pharma doses first patient in cystic fibrosis trial pharmatimes
April 07, 2017
Verona Pharma has enrolled and dosed the first patient in a clinical study assessing its investigational drug RPL554 as a treatment for cystic fibrosis (CF).

Previous page 1 2 3 4 5 Next page